Cytosolic Levels of An Estrogen-Induced Breast Cancer-Associated Peptide (TFF1/pS2) in Colorectal Cancer: Clinical Significance and Relationship with Steroid Receptors
Free accessResearch articleFirst published online October, 2003
Cytosolic Levels of An Estrogen-Induced Breast Cancer-Associated Peptide (TFF1/pS2) in Colorectal Cancer: Clinical Significance and Relationship with Steroid Receptors
The Trefoil Factor 1 (TFF1/pS2), a peptide consisting of 60 amino acids, is the most abundant estrogen-induced messenger RNA in MCF-7 breast cancer cells and is also expressed by colorectal carcinomas. The objective of this work was to evaluate the cytosolic TFF1 content in colorectal carcinomas, its possible relationship with estrogen and progesterone receptors as well as with clinicopathological tumor parameters, and its potential prognostic significance.
Methods
Cytosolic TFF1 levels were examined by immunoradiometric assay in 178 patients with resectable colorectal cancer. The mean follow-up period was 32 months.
Results
There was a wide variability of cytosolic TFF1 levels in tumor-surrounding mucosa samples (0.09-42.5 ng/mg protein) as well as in tumors (0.01-270 ng/mg protein). Comparison of paired mucosa and carcinoma samples showed significantly higher TFF1 levels in tumors (mean: 17.1 ng/mg protein) than in mucosa samples (10 ng/mg protein) (p=0.027). TFF1 levels were significantly higher in mucosa samples surrounding distal colon and rectal tumors (p=0.0001) and in tumor samples obtained from older patients (p=0.007). However, there were no significant differences in tumor TFF1 levels with respect to clinicopathological parameters such as the patient's sex, tumor location, stage, histological grade, ploidy, S-phase, or tumor estrogen and progesterone receptors. In addition, there was no significant relationship between tumor TFF1 levels and disease outcome.
Conclusions
TFF1 may play an as yet undetermined role in the tumorigenesis of colorectal carcinomas. However, cytosolic levels of TFF1 do not seem to have any prognostic significance in colorectal carcinomas.
MasiakowskiP., BreathnachR., BlochJ., GannonF., KrustA., ChambonP.Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res1982; 10: 7895–903.
5.
RioM.C., BellocqJ.P., DanielJ.Y.. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science1988; 241: 705–8.
6.
LuqmaniY., BennettC., PatersonI.. Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer1989; 44: 806–12.
7.
TheisingerB., WelterC., GrzeschikK.H., BlinN.Assignment of the gene for human spasmolytic protein (hSP/SML1) to chromosome 21. Hum Genet1992; 89: 681–2.
8.
MullerW., BorchardF.pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival. J Pathol1993; 171: 263–9.
9.
HanbyA.M., PoulsomR., EliaG., SinghS., LongcroftJ.M., WrightN.A.The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in ‘gastric metaplasia’ of the proximal duodenum: implications for the nature of ‘gastric metaplasia’. J Pathol1993; 169: 355–60.
10.
PalludC., Le DoussalV., PichonM.F., Prud'hommeJ.F., HaceneK., MilgromE.Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histopathology1993; 23: 249–56.
11.
HahnelE., RobbinsP., HahnelR.Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat1993; 28: 295–7.
12.
JakowlewS.B., BreathnachR., JeltschJ.M., MasiakowskiP., ChambonP.Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res1984; 12: 2861–78.
13.
RioM.C., ChambonP.The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells1990; 2: 269–74.
14.
ThompsonA.M., HawkinsR.A., EltonR.A., SteelC.M., ChettyU., CarterD.C.pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer1993; 68: 93–6.
15.
SpyratosF., AndrieuC., HaceneK., ChambonP., RioM.C.pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer1994; 69: 394–7.
16.
SoubeyranI., QuenelN., CoindreJ.M.. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer1996; 74: 1120–5.
17.
HigashiyamaM., DoiO., KodamaK.. Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Eur J Cancer1994; 6: 792–7.
18.
HigashiyamaM., DoiO., KodamaK., YokuchiH., InajiH., TateishiR.Estimation of serum level of pS2 protein in patients with lung adenocarcinoma. Anticancer Res1996; 16: 2351–5.
19.
WelterC., TheisingerB., SeitzG.. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest1992; 66: 187–92.
20.
CollierJ.D., BennettM.K., BassendineM.F., LendrumR.Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. J Gastroenterol Hepatol1995; 10: 396–400.
21.
BonkhoffH., SteinU., WelterC., RembergerK.Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol1995; 26: 824–8.
22.
LipponenP.K., EskelinenM.J.Expression of pS2 protein in transitional cell bladder tumours. J Pathol1994; 173: 327–32.
23.
WangD.G., LiuW.H., LundyF.T.. TFF1 gene expression in human medullary thyroid carcinoma. J Pathol1998; 184: 408–13.
24.
HanbyA.M., McKeeP., JefferyM.. Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors. Am J Surg Pathol1998; 22: 1125–31.
25.
WysockiS.J., HahnelE., MastersA., SmithV., McCartneyA.J., HahnelR.Detection of pS2 messenger RNA in gynecological cancers. Cancer Res1990; 50: 1800–2.
26.
SinghS., PoulsomR., WrightN.A., SheppardM.C., LangmanM.J.Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer. Gut1997; 40: 516–20.
27.
SuarezC., VizosoF., RodriguezJ.C.. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int J Biol Markers2001; 16: 37–44.
28.
WilliamsR., StampG.W., GilbertC., PignatelliM., LalaniE.N.pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3-D collagen gel. J Cell Sci1996; 109: 63–71.
29.
Bossenmeyer-PourieC., KannanR., RibierasS.. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol2002; 157: 761–70.
30.
ShoushaS., LuqmaniY.A., SanninoP., RioM.C., CoombesR.C., TheodorouN.A.pS2 immunostaining of colorectal carcinoma. Mod Pathol1993; 6: 446–8.
31.
HackelC., FalkenbergB., GuntherT., LippertH., RoessnerA.The pS2 protein in colorectal carcinomas and metastases. Pathol Res Pract1998; 194: 171–6.
32.
WelterC., TheisingerB., RioM.C., SeitzG., SchuderG., BlinN.Expression pattern of breast-cancer-associated protein pS2/BCEI in colorectal tumors. Int J Cancer1994; 56: 52–5.
33.
JuncoA., RodriguezJ.C., AllendeM.T., Garcia-MunizJ.L., GonzalezJ.J., VizosoF.The pS2 protein in primary colorectal carcinomas and in surrounding mucosa. Int J Biol Markers1999; 14: 189–91.
34.
HerrmannJ.B.Breast cancer and associated extramammary malignant neoplasms. Am J Surg1972; 124: 620–4.
35.
PotterJ.D., SlatteryM.L., BostickR.M., GapsturS.M.Colon cancer: a review of the epidemiology. Epidemiol Rev1993; 15: 499–545.
36.
WingoP.A., RiesL.A., ParkerS.L., HeathC.W.Jr.. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev1998; 7: 271–82.
37.
Hebert-CroteauN.A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev1998; 7: 653–9.
38.
MeggouhF., LointierP., SaezS.Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res1991; 51: 1227–33.
39.
SinghS., SheppardM.C., LangmanM.J.Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut1993; 34: 611–5.
40.
FoleyE.F., JazaeriA.A., ShupnikM.A., JazaeriO., RiceL.W.Selective loss of estrogen receptor beta in malignant human colon. Cancer Res2000; 60: 245–8.
41.
RaigosoP., SanzL., VizosoF.. Estrogen and progesterone receptors in colorectal cancer and surrounding mucosa. Int J Biol Markers2001; 16: 262–7.
42.
CavalliniA., MessaC., PricciM., CarusoM.L., BaroneM., Di LeoA.Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. Dig Dis Sci2002; 47: 2720–8.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem1976; 72: 248–54.
48.
RaigosoP., JuncoA., AndicoecheaA.. Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. Int J Biol Markers2000; 15: 44–50.
49.
KaplanE., MeierP.Nonparametric estimation from incomplete observations. J Am Stat Assoc1958; 53: 457–81.
50.
MantelN., MyersM.Problems of convergence of maximun likehood iterative procedures in multiparameter situations. J Am Stat Assoc1971; 66: 484–91.
51.
RioM.C., ChenardM.P., WolfC.. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology1991; 100: 375–9.
52.
WrightN.A., PoulsomR., StampG.. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology1993; 104: 12–20.
53.
TomasettoC., WolfC., RioM.C.. Breast cancer protein PS2 synthesis in mammary gland of transgenic mice and secretion into milk. Mol Endocrinol1989; 3: 1579–84.
54.
SinghS., PoulsomR., HanbyA.M.. Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer. J Pathol1998; 184: 153–60.
55.
HenryJ.A., BennettM.K., PiggottN.H., LevettD.L., MayF.E., WestleyB.R.Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer1991; 64: 677–82.
56.
PoulsomR., HanbyA.M., LalaniE.N., HauserF., HoffmannW., StampG.W.Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol1997; 183: 30–8.
57.
GillesbyB.E., ZacharewskiT.R.pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat1999; 56: 253–65.
58.
NogueiraA.M., MachadoJ.C., CarneiroF., ReisC.A., GottP., Sobrinho-SimoesM.Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol1999; 187: 541–8.
59.
ThompsonA.M., EltonR.A., HawkinsR.A., ChettyU., SteelC.M.PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer. Br J Cancer1998; 77: 492–6.
60.
dos Santos SilvaE., UlrichM., DoringG., BotzenhartK., GottP.Trefoil factor family domain peptides in the human respiratory tract. J Pathol2000; 190: 133–42.
61.
BrownA.M., JeltschJ.M., RobertsM., ChambonP.Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci U S A1984; 81: 6344–8.
62.
BaldwinW.S., TravlosG.S., RisingerJ.I., BarrettJ.C.Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis1998; 19: 1895–900.
63.
BerryM., NunezA.M., ChambonP.Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A1989; 86: 1218–22.
64.
SonnenscheinC., SzeleiJ., NyeT.L., SotoA.M.Control of cell proliferation of human breast MCF7 cells; serum and estrogen resistant variants. Oncol Res1994; 6: 373–81.
65.
BadiaE., DuchesneM.J., SemlaliA.. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res2000; 60: 4130–8.
66.
MartinV., RibierasS., Song-WangX.G.. Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J Cell Biochem1997; 65: 95–106.
67.
EmamiS., Le FlochN., BruyneelE.. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. Faseb J2001; 15: 351–61.
68.
PrestS.J., MayF.E., WestleyB.R.The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. Faseb J2002; 16: 592–4.
69.
LefebvreO., ChenardM.P., MassonR.. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science1996; 274: 259–62.
70.
CalnanD.P., WestleyB.R., MayF.E., FloydD.N., MarchbankT., PlayfordR.J.The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol1999; 188: 312–7.
